Last reviewed · How we verify
AL-001
AL-001 is a small molecule that targets the SGLT2 receptor.
AL-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AL-001 |
|---|---|
| Sponsor | Beijing Anlong Biopharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, AL-001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) (PHASE3)
- Continuation Study for Latozinemab (PHASE3)
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects (PHASE1)
- A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) (PHASE2)
- A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS (PHASE2)
- Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects (PHASE1, PHASE2)
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD (PHASE1, PHASE2)
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL-001 CI brief — competitive landscape report
- AL-001 updates RSS · CI watch RSS
- Beijing Anlong Biopharmaceutical Co., Ltd. portfolio CI